新股孖展 | 數科集團融資認購超50倍,有望成年內“超購王”
uSMART9月15日消息,綜合部分券商數據,截至9月15日15時,數科集團(2350)錄得孖展額約6.7億港元,以公開發售募資額0.13億港元算,公開認購超50倍。

今年認購倍數最高的新股爲微創腦科學45.27倍,其次爲玄武雲42.13倍,數科集團有望超越前者成爲今年認購倍數最高的新股。
數科集團是一間於香港成立的資訊科技解決方案供應商,主要從事於中國香港分銷資訊科技產品以及於中國、中國香港及中國澳門提供系統整合解決方案。每股發售價範圍0.80-0.86港元,每手5000股,入場費4343.35港元,發行市值5-5.38億港元,創升融資爲獨家保薦人。總體來看,今年的小市值細價新股表現較優。
uSMART融資認購截止時間爲9月15日18:00,現金認購截止時間爲9月16日9:00,該股份預計將於9月26日掛牌上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.